In the news

Source: Press release

Doctors in the US have used whole genome sequencing (WGS) to direct the treatment of a pancreatic cancer patient. 

Clinicians at the Mayo Clinic worked with the company TGen to sequence and compare the normal and tumour cell genomes from the patient using WGS technologies. Identification of key mutations in the cancer cells reportedly allowed them to select a therapy specifically directed against them, although no details are given (said to be ‘included in an upcoming scientific paper’).

Although this particular report is not very informative, we are certain to see more and more examples of the use of WGS in clinical settings (as opposed to research studies), to improve characterisation of rare genetic causes of disease, and the specific genetic nature of individual tumours. In many cases this may allow doctors to choose treatments that are more likely to be effective. The feasibility of clinical applications will depend on a range of key issues – currently the subject of a PHG Foundation project - including cost and logistics.